News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synthetic Biologics, Inc. (SYN) To Present At The 7th Annual OneMedForum San Francisco 2014 Conference


1/9/2014 6:22:13 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

ROCKVILLE, Md., Jan. 8, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 7th Annual OneMedForum San Francisco 2014 conference next week in San Francisco, as follows:

Date: Tuesday, January 14, 2014
Time:11:30 a.m. (PT)/2:30 p.m. (ET)
Location: The Westin San Francisco Market Street Hotel

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the internet at http://onemedplace.com/forum/webcast/. After the presentation, a replay will be archived and accessible for 30 days at the same website.

(Logo: http://photos.prnewswire.com/prnh/20130522/MM19465LOGO)

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of product candidates for serious infectious and other diseases. Synthetic Biologics is developing oral treatments targeting archaea, a non-bacterial intestinal form of life increasingly associated with chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes, an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of C. diff infection, a series of monoclonal antibodies (mAbs) for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of IBS. In addition, the Company is developing an oral estriol drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS (with results of an ongoing 164 subject, 15 center, two-year, double blind, placebo controlled, Phase II relapsing-remitting MS clinical trial expected to be announced during the first half of 2014). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

SOURCE Synthetic Biologics, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES